4-Hydroxytamoxifen

guinea pig

Also seen as: 4-OHT

The Dose Guy’s verdict

Sep 1, 2026
3 sources

The concept makes sense: take the active metabolite of tamoxifen and rub it directly on the tissue you want to treat, skipping the liver and the systemic side effects. In practice, the human data is thin and the one rigorous trial failed to match oral tamoxifen. If you are running it topically for gyno, you are betting on pharmacology, not proof. Most people should just take tamoxifen by mouth.

Would I take it?Caution, interesting idea, thin proof.

What it is

4-Hydroxytamoxifen is one of the active metabolites your body makes when you take tamoxifen. It binds the estrogen receptor directly without needing CYP2D6 to activate it, which is the whole appeal of using it as a standalone: you skip the genetic lottery that makes tamoxifen work well in some people and poorly in others. Clinically, it has been developed as afimoxifene, a breast-applied gel for localized estrogen blockade.

The community interest is narrower. People buy it as a research chemical and apply it to the chest to shrink or prevent gyno without the hot flashes, mood effects, and clotting risk of systemic tamoxifen. The logic is sound. The problem is that the human evidence for topical delivery to deep breast tissue is underwhelming, and the largest trial found the gel did not match oral tamoxifen for antiproliferative effect.

What the research shows

The human data is small, clinical, and not encouraging for the community’s use case:

In a presurgical DCIS trial, transdermal 4-hydroxytamoxifen did not establish antiproliferative noninferiority to oral tamoxifen. Posttreatment Ki-67 was 3.3 percentage points higher with the gel, exceeding the noninferiority margin.JAMA Surgery 2023 · phase 2 RCT · n=100

In premenopausal women with cyclical mastalgia, 4 mg daily topical afimoxifene improved pain VAS by 12.71 mm versus placebo, with no changes in menstrual pattern or plasma hormones.Breast Cancer Res Treat 2007 · phase 2 RCT

A systematic review found only three transdermal versus oral tamoxifen trials totaling 103 participants and could not conclude that topical 4-hydroxytamoxifen should be used for breast cancer treatment because the study base was limited.IJSC 2019 · systematic review · 3 trials · n=103

Median deep-breast endoxifen was 0.3 ng/g with the gel versus 13.0 ng/g with oral tamoxifen. The gel delivers the parent compound locally but skips the downstream metabolite that does much of oral tamoxifen’s work.JAMA Surgery 2023 · phase 2 RCT · n=100 · tissue PK

Realistic protocols

I am not going to pretend the evidence supports a confident protocol here. The aim is local estrogen blockade at the breast without systemic drug levels, and the logic is sound.

The practical reality is mixed. Some people report gyno shrinkage on topical 4-hydroxytamoxifen. Some report nothing. The endoxifen gap in the tissue data above is the strongest reason to doubt the topical route, but whether that gap matters for gyno, which is a different target than DCIS, nobody has tested.

If you run it anyway, keep the course short, log what you see, and have oral tamoxifen or raloxifene on hand as a fallback if the lump does not move. Do not stack it with oral tamoxifen, that defeats the purpose of going topical.

The evidence does not support a dosing table. Community protocols run 10 to 25 mg topically to the chest once or twice daily for four to twelve weeks. If gyno is not responding after six weeks, switch to oral tamoxifen or raloxifene. This is experimental, not established.

Side effects

The topical route avoids most of systemic tamoxifen’s side effects, which is the point:

commonSkin irritation at the application site. Mild and usually tolerable.

anecdotalSome users report a pulling or tingling sensation at the gyno site, interpreted as the drug working. Not validated.

unknownNo human safety study exists for the way the community uses this compound. Systemic absorption at higher topical doses is possible and unmeasured.

Where to buy

No live listings from tracked vendors right now.